课题基金 / 基金详情

Targeting secreted factors in endocrine resistant breast cancer therapy

Targeting secreted factors in endocrine resistant breast cancer therapy
内分泌耐药乳腺癌治疗中的靶向分泌因子
批准号:
10654343
负责人:
Kideok Jin
金额:
$48.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2026-03-31
关键词:
AntibodiesAntineoplastic AgentsAromatase InhibitorsAutomobile DrivingBindingBioinformaticsBiological AssayBiological MarkersBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineBreast Cancer therapyCCR5 geneCDK4 geneCRISPR/Cas technologyCell CommunicationCell LineCell ProliferationCellsClinicalCoculture TechniquesCombined Modality TherapyCommunicationConduct Clinical TrialsDiseaseDrug TargetingDrug resistanceESR1 geneEndocrineEndoglinEstrogen ReceptorsEstrogen receptor positiveFeedbackFibroblastsFulvestrantFutureGrowthInvadedInvestigationKnock-outKnowledgeLigand Binding DomainLymphatic Endothelial CellsMAPK Signaling Pathway PathwayMacrophageMalignant NeoplasmsMammary NeoplasmsMetastatic breast cancerMethodsMigration AssayMolecular TargetMusMutationNeoplasm MetastasisOrganOutcomes ResearchPatientsPharmaceutical PreparationsPhenotypePlayPoint MutationPostmenopauseProtein SecretionRANTESRecurrenceRegimenResistanceResistance developmentRoleSecondary toSignal PathwaySignal TransductionSolid NeoplasmStromal CellsSystemTamoxifenTestingTherapeuticTissuesTubeUp-RegulationVascular Endothelial CellWomanXenograft procedurecancer clinical trialcell motilitycell stromacytokinedesigndiagnostic biomarkerdimethylbenzanthraceneeffective therapyexperimental studygenome editinghormone therapyinhibitorinhibitor therapymalignant breast neoplasmmouse modelneoplastic cellnew therapeutic targetnovelparacrinepre-clinicalreceptorscreeningtherapeutic targettranscription factortumortumor DNAtumor growth

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
摘要/总结:
英文摘要
Abstract/Summary: Various types of endocrine therapy have been used for postmenopausal women with early stage breast cancer. These therapies are safe and effective, but initially responsive breast tumors often develop resistance and eventually recur. Since a communication between tumor and tumor circumstance plays an important role to grow tumor and spread tumor to secondary organs, we examined the communication of endocrine resistant breast cancer with stroma which is the part of a tissue or organ that has a connective and structural role in cancer. We established four different endocrine resistant breast cancer cell lines and examined the communication of these cells with four stromal cells. We found that CCL5 and endoglin might play an important role in endocrine resistant breast cancer. Thus, we will 1) Investigate the role of CCL5 and endoglin in the crosstalk between ERBC cells and stromal cells, 2) Unveil the mechanism of the upregulated CCL5 and endoglin in crosstalk between ERBC and stroma, and 3) Develop therapeutic strategies to block the paracrine interaction between the stromal cell and ERBC cell. We will investigate which secreted factors could serve as a key regulator in the transition of breast cancer cells to endocrine resistance and gaining of an aggressive phenotype. Further, secreted factors from the communication between endocrine resistant breast cancer and stroma might prove to be an attractive target for breast cancer drugs. Most of the cancer drugs in use currently have been developed to directly impact tumor cells. These drugs do not do much to block signals coming from tumor circumstance. Our proposed investigation will give us a small list of the most potent of these signals. Drugs, some of which we will identify here, and others that will have to be developed, that block these signals could limit the ability of the tumors to spread to secondary organs, which should result in overall survival gains for patients.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.18632/oncotarget.28397
发表时间: 2023-03-31
期刊: ONCOTARGET
影响因子: --
作者: [Smrekar, Karly, Belyakov, Artem, Jin, Kideok]
通讯作者: Jin, Kideok
海外基金